There are currently 18 clinical trials in Rialto, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Inland Empire Liver Foundation and Inland Empire Clinical Trials, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181
Recruiting
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Inland Empire Clin Trials LLC, Rialto, California
Conditions: Non-alcoholic Steatohepatitis
Register for Updates
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
NCT06054815
Recruiting
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Inland Empire Clinical Trials, LLC, Rialto, California
Conditions: NON-ALCOHOLIC STEATOHEPATITIS
Register for Updates
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03464097
Recruiting
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Local Institution - 006, Rialto, California
Conditions: Crohn Disease
Register for Updates
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition
NCT05519475
Recruiting
This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have non-alcoholic steatohepatitis (NASH). NASH is a form of non-alcoholic fatty liver disease (NAFLD). Recently, the name metabolic dysfunction associated steatohepatitis (MASH) has been introduced to replace NASH and metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD. NASH occurs when fat builds up in liver cells, damaging... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: Inland Empire Liver Foundation, Rialto, California
Conditions: Non-alcoholic Steatohepatitis (NASH), Metabolic Dysfunction Associated Steatohepatitis (MASH)
Register for Updates
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
NCT05919069
Recruiting
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Research Site, Rialto, California
Conditions: Hepatic Impairment
Register for Updates
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
NCT05763576
Recruiting
This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics following single and/or multiple doses of RO7565020 in healthy participants and/or virologically suppressed participants with chronic hepatitis B (CHB).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: Inland Empire Liver Foundation, Rialto, California
Conditions: Chronic Hepatitis B
Register for Updates
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
Recruiting
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin for the treatment of liver fibrosis stage 2 or 3 in adult participants with MASH (previously known as nonalcoholic steatohepatitis [NASH]).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2024
Locations: 89bio Clinical Study Site, Rialto, California
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Register for Updates
Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/01/2024
Locations: 89bio Clinical Study Site, Rialto, California
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Register for Updates
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
NCT03467958
Recruiting
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2024
Locations: Local Institution - 006, Rialto, California
Conditions: Crohn Disease
Register for Updates
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945
Recruiting
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/27/2024
Locations: Inland Empire Clinical Trials, LLC, Rialto, California
Conditions: Ulcerative Colitis
Register for Updates
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
NCT05751759
Recruiting
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/08/2024
Locations: Research Site, Rialto, California
Conditions: Hepatic Impairment
Register for Updates
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
NCT05484206
Recruiting
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/01/2024
Locations: Inland Empire Clinical Trials, Rialto, California
Conditions: Hepatic Impairment, Cirrhosis
Register for Updates